Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo purchased 53,260 shares of the stock in a transaction dated Wednesday, May 24th. The shares were acquired at an average price of GBX 5 ($0.07) per share, for a total transaction of £2,663 ($3,464.29).

Lorenzo Tallarigo also recently made the following trade(s):

  • On Monday, April 24th, Lorenzo Tallarigo purchased 54,090 shares of Oxford BioMedica plc stock. The shares were acquired at an average price of GBX 5 ($0.07) per share, for a total transaction of £2,704.50 ($3,518.28).
  • On Thursday, March 23rd, Lorenzo Tallarigo purchased 49,468 shares of Oxford BioMedica plc stock. The shares were acquired at an average price of GBX 5 ($0.07) per share, for a total transaction of £2,473.40 ($3,217.64).
  • On Friday, February 24th, Lorenzo Tallarigo acquired 67,165 shares of Oxford BioMedica plc stock. The shares were purchased at an average cost of GBX 4 ($0.05) per share, with a total value of £2,686.60 ($3,494.99).

Oxford BioMedica plc (LON:OXB) traded up 2.04% during mid-day trading on Wednesday, reaching GBX 5.00. The company had a trading volume of 1,784,606 shares. Oxford BioMedica plc has a 12 month low of GBX 2.98 and a 12 month high of GBX 6.00. The stock’s market cap is GBX 154.20 million. The firm’s 50-day moving average price is GBX 4.87 and its 200-day moving average price is GBX 4.34.

Insider Buying and Selling by Quarter for Oxford BioMedica plc (LON:OXB)

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/05/24/oxford-biomedica-plc-oxb-insider-acquires-2663-in-stock.html.

A number of analysts recently issued reports on the company. N+1 Singer reissued a “hold” rating and set a GBX 3.30 ($0.04) price objective on shares of Oxford BioMedica plc in a research report on Thursday, March 16th. Jefferies Group LLC reissued a “buy” rating and set a GBX 8 ($0.10) price objective on shares of Oxford BioMedica plc in a research report on Friday, March 17th.

About Oxford BioMedica plc

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

12 Month Chart for LON:OXB

Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.